Targeted cancer therapies and immunotherapies are advancing. A recent article discusses emerging trends in these areas for lung cancer and melanoma, including new targeted drugs and immune checkpoint inhibitors that have improved survival. The article from July 2015 analyzes developing approaches in targeted therapies and immunotherapies for these cancers.
Project IBSL for STEM club Evangeliki Model High School of Smyrna.
Using Resources by STEM Alliance repository.
“Skin cancer into the research microscope of students”.
Project IBSL for STEM club Evangeliki Model High School of Smyrna.
Using Resources by STEM Alliance repository.
“Skin cancer into the research microscope of students”.
An innovative clinical trail study design _First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Cancer treatment using biotechnology
what does cancer mean to you?
problem statement
biotechnological drugs for cancer treatment
1- monoclonal antibodies
2- gene therapy
CAR-T- the ultimate therapy
3- therapeutic proteins
4- nanorobots
current and future perspective
achievements
references
Descripción de diversas herramientas para el análisis de datos masivos (Real World Data) de las Comorbilidades en la Historia Clínica Electrónica (HCE). Ponencia invitada en el Summer School de la Universidad de Barcelona (UB), 5 julio 2019. Hospital Clínico de Barcelona.
OMICS Publishing Group, Journal of Carcinogenesis & Mutagenesis features the critical reviews focused on topics of significant interest to specialists in cancer biology and mutation research, scope of the journal reflects the rapid advances in the field of mutation research and latest developments in gene therapy for cancer.
International Journal of Cancer Studies & Research (IJCR) ISSN:2167-9118 is a comprehensive, peer reviewed journal devoted to cancer studies and research. IJCR, published by SciDoc is an open access journal that includes high quality papers, which covers all major areas of Cancer and its related fields. SciDoc with its Open Access publication model spreads all the day-to-day developments and research to readers around the world.
An innovative clinical trail study design _First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Cancer treatment using biotechnology
what does cancer mean to you?
problem statement
biotechnological drugs for cancer treatment
1- monoclonal antibodies
2- gene therapy
CAR-T- the ultimate therapy
3- therapeutic proteins
4- nanorobots
current and future perspective
achievements
references
Descripción de diversas herramientas para el análisis de datos masivos (Real World Data) de las Comorbilidades en la Historia Clínica Electrónica (HCE). Ponencia invitada en el Summer School de la Universidad de Barcelona (UB), 5 julio 2019. Hospital Clínico de Barcelona.
OMICS Publishing Group, Journal of Carcinogenesis & Mutagenesis features the critical reviews focused on topics of significant interest to specialists in cancer biology and mutation research, scope of the journal reflects the rapid advances in the field of mutation research and latest developments in gene therapy for cancer.
International Journal of Cancer Studies & Research (IJCR) ISSN:2167-9118 is a comprehensive, peer reviewed journal devoted to cancer studies and research. IJCR, published by SciDoc is an open access journal that includes high quality papers, which covers all major areas of Cancer and its related fields. SciDoc with its Open Access publication model spreads all the day-to-day developments and research to readers around the world.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Ten new cancer drugs were launched globally in 2014, including the two new checkpoint inhibitor immunotherapies nivolumab and pembrolizumab, blinatumomab, ramucirumab, and siltuximab. However, not all launches occurred in all countries; for example, alectinib and mogamulizumab were made available in Japanese markets only. New options will soon be available for additional patients, as many of the new agents will eventually be approved for multiple indications. Image credit: IMS Health MIDAS Dec. 2014.
The field of immuno-oncology is still in its early stages, but new therapies and classes of agents have emerged in waves that heighten with each new development. Ipilimumab is an example of a new immunotherapy leading the charge with other PD-1–targeted agents that have been approved for the treatment of metastatic melanoma. In addition, chimeric antigen receptor T cells, cell-based therapies that condition a patient’s T cells to recognize a specific cancer, are poised to change the treatment armamentarium for hematologic cancers in the near future. Image credit: IMS Health European Thought Leadership.
Over the next 6 years, there is expected to be a surge in the number of combination targeted and immuno-oncology agents available on the market. In the first few years, breast and hematology combinations will predominate, and after 2018, combinations targeting solid tumors such as lung cancer and melanoma will drastically increase. Image credit: CenterWatch, FDA, clinicaltrials.gov, IMS R&D LifeCycle, IMSCG Analysis.
With new combination therapies, come new levels of complexity in terms of development and marketing for these new molecular entities, since most combinations come from two or more manufacturers. Not only can this complicate trial and commercialization strategies, but pricing flexibility and product promotion can also be affected. Currently, only four pharmaceutical companies (Roche, Bristol-Myers Squibb, AstraZeneca, and Janssen) are studying combinations of new molecular entities and an existing agent that are produced by a single manufacturer. Image credit: CenterWatch, FDA, clinicaltrials.gov, IMS R&D LifeCycle, IMSCG Analysis. - See more at: http://www.oncotherapynetwork.com/cancer-and-genetics/slide-show-trends-targeted-therapies-and-immunotherapies?GUID=0CC5B497-4098-44AA-AC04-9DA0AAB2D8FB&rememberme=1&ts=25082015#sthash.e1TRwqFN.dpuf
There are currently 100 active phase II and III trials for five mechanisms of action, which target 11 key tumors. These investigations include new molecular entities and new indications for drugs that are already on the market. Although many of the new molecular entities will not reach approval, those with proven activity (e.g., VEGF and PD/PD-1 inhibitors) will result in more indications. Image credit: IMS Health R&D Focus. - See more at: http://www.oncotherapynetwork.com/cancer-and-genetics/slide-show-trends-targeted-therapies-and-immunotherapies?GUID=0CC5B497-4098-44AA-AC04-9DA0AAB2D8FB&rememberme=1&ts=25082015#sthash.e1TRwqFN.dpuf
Non–small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is an example of a disease in which patients are now being divided into groups defined by specific genetic mutations; however, those mutations can evolve and become resistant to therapy. Second- and third-generation targeted therapies for NSCLC offer the potential for multiple years of treatment with good quality of life. Immuno-oncology agents are also gaining traction for this indication; nivolumab has been recently approved and data indicate it is efficacious in non-squamous NSCLC as well. Image credit: IMS Health R&D Focus, clinicaltrials.gov company websites Dec. 2014. - See more at: http://www.oncotherapynetwork.com/cancer-and-genetics/slide-show-trends-targeted-therapies-and-immunotherapies?GUID=0CC5B497-4098-44AA-AC04-9DA0AAB2D8FB&rememberme=1&ts=25082015#sthash.e1TRwqFN.dpuf
Dividing patients into genetic subgroups is resulting in a new method of investigation, dubbed “basket studies.” These trials are meant to inform a broader clinical development program by pooling patients with different cancers, but well-established common molecular signatures into a single trial. Not only are these trials cost-effective, but they focus on overall response to the agent, and therefore can provide evidence for approval in rare cancers in which the genetic target is known but the unmet need for treatment is high. Image credit: IN VIVO, May 2014, Novel Clinical Trial Designs in Oncology: An Histology-Independent Approach. - See more at: http://www.oncotherapynetwork.com/cancer-and-genetics/slide-show-trends-targeted-therapies-and-immunotherapies?GUID=0CC5B497-4098-44AA-AC04-9DA0AAB2D8FB&rememberme=1&ts=25082015#sthash.e1TRwqFN.dpuf